Observational studyScientific reports2026
Impact of liver cirrhosis etiology on results of diagnostic tests for minimal hepatic encephalopathy.
Observational study in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The influence of cirrhosis etiology on minimal hepatic encephalopathy (mHE) testing and prediction of overt hepatic encephalopathy (oHE) remains unclear. We investigated the impact of cirrhosis etiology on mHE testing and its predictive value for oHE. In this observational study, 312 patients with liver cirrhosis underwent six mHE tests: Portosystemic Encephalopathy Test yielding the PHES, Animal Naming Test, Critical Flicker Frequency, Inhibitory Control Test, EncephalApp, and Continuous Reaction Time. Etiologies included alcohol-related liver disease (ALD), metabolic dysfunction-associated steatohepatitis (MASH), metabolic/alcohol-associated liver disease (MetALD), infectious/autoimmune liver disease (IALD), and cryptogenic/other (CRYO). Multivariable regression models adjusted for relevant confounders were used to analyze etiology-related differences. Predictive value for oHE was assessed over one year using competing risk models. Patients with IALD performed significantly better on PHES than ALD patients (adjusted β: 1.8, [0.5-3]). PHES scores were comparable across steatotic etiologies. PHES showed moderate predictive value for oHE in steatotic (ALD sHR: 2.2 [1.0–4.9]; MASH: 3.4 [1.3–8.8]; MetALD: 2.5 [0.8–8.0]) but strong predictive value in non-steatotic etiologies (IALD sHR: 5.7 [2.2–14.7]; CRYO: 5.8 [1.2–29.3]) Other tests showed only minor etiology-related differences. Cirrhosis etiology may influence PHES results and its predictive value for oHE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.